APOC3 RNAi Conjugates for Liver-Targeted Triglyceride Lowering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertriglyceridemia and related conditions, such as hypertriglyceridemia-induced pancreatitis and atherosclerosis, are inadequate, particularly for patients with monogenic causes of very severe hypertriglyceridemia, as they fail to provide substantial TG lowering effects due to dysfunctional lipoprotein lipase.
Innovation Solution
Development of APOC3-specific RNAi agents that selectively and efficiently inhibit APOC3 gene expression, reducing TG and cholesterol levels through targeted delivery to liver cells using conjugated ligands, such as asialoglycoprotein receptor ligands, and administration methods like subcutaneous injection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments (fibrates, statins) are used for hypertriglyceridemia, then some lipid lowering effect is achieved, but the TG lowering effect is modest and insufficient for severe cases
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism by designing RNAi agents that selectively inhibit APOC3 gene expression. This extraction of the specific target (APOC3) from the complex lipid metabolism system enables precise intervention, achieving substantial TG lowering effects (50-80% reduction) that conventional broad-spectrum treatments cannot achieve.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific lipid lowering to specific APOC3 gene suppression. By modifying the treatment mechanism from enzyme inhibition (fibrates/statins) to gene expression suppression (RNAi), the patent achieves a qualitative change in treatment efficacy, transforming modest effects into substantial TG reduction.
2Reliability
If APOC3 RNAi agents are administered systemically, then gene expression inhibition is achieved, but off-target effects and reduced specificity may occur
Solution Approach 1:
The patent applies local quality by conjugating the RNAi agent to liver-targeting ligands (asialoglycoprotein receptor ligands, galactose derivatives). This creates a heterogeneous structure where only the liver-specific portion interacts with target cells, ensuring that gene suppression occurs locally in the liver where APOC3 is primarily expressed, while minimizing systemic off-target effects.
Solution Approach 2:
The patent introduces liver-targeting ligands as intermediaries between the RNAi agent and liver cells. These ligands act as mediators that guide the RNAi complex specifically to hepatocytes via receptor-mediated endocytosis, preventing random distribution and off-target effects throughout the body.
3Reliability
If RNAi agents are designed for high potency, then complex molecular structures are required, but manufacturing complexity increases
Solution Approach 1:
The patent creates composite RNAi structures by combining siRNA duplexes with liver-targeting ligands and protective moieties (phosphorothioate modifications, 2'-O-methyl modifications). This composite approach achieves high potency and specificity while using modular components that can be synthesized separately and assembled, facilitating manufacturing compared to designing entirely novel complex molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The APOC3 RNAi agents effectively reduce TG and cholesterol levels, providing therapeutic benefits for conditions like obesity, hyperlipidemia, atherosclerosis, and cardiovascular disease, including severe hypertriglyceridemia, by inhibiting APOC3 gene expression and enhancing treatment efficacy.
Implementation Method 1
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
Implementation Method 2
targeted delivery to liver cells using conjugated ligands, such as asialoglycoprotein receptor ligands
Data Source
AI summary
The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, capable of inhibiting Apolipoprotein C-III (also called APOC3, apoC-III, APOC-III, and APO C-III) gene expression, and compositions that include APOC3 RNAi agents. The APOC3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that include N-acetyl-galactosamine, to facilitate the delivery to cells, including to hepatocytes. Pharmaceutical compositions that include one or more APOC3 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the APOC3 RNAi agents in vivo provides for inhibition of APOC3 gene expression, and can result in lower triglycerides and/or cholesterol levels in the subject. The APOC3 RNAi agents can be used in methods of treatment of APOC3-related diseases and disorders, including hypertriglyceridemia, cardiovascular disease, and other metabolic-related disorders and diseases.